Inspire Investing LLC Reduces Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Inspire Investing LLC trimmed its stake in United Therapeutics Co. (NASDAQ:UTHR) by 30.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,065 shares of the biotechnology company’s stock after selling 3,151 shares during the period. Inspire Investing LLC’s holdings in United Therapeutics were worth $2,532,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. ClariVest Asset Management LLC lifted its position in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 42 shares during the period. USA Financial Formulas purchased a new position in United Therapeutics during the 3rd quarter valued at about $33,000. V Square Quantitative Management LLC purchased a new position in United Therapeutics during the 2nd quarter valued at about $30,000. Innealta Capital LLC purchased a new position in United Therapeutics during the 2nd quarter valued at about $33,000. Finally, Rise Advisors LLC purchased a new position in United Therapeutics during the 1st quarter valued at about $32,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $358.22 on Friday. The firm has a 50 day moving average of $346.73 and a 200 day moving average of $303.78. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $15.94 billion, a price-to-earnings ratio of 16.46, a price-to-earnings-growth ratio of 1.29 and a beta of 0.57. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $366.08.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). The business had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The business’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter last year, the firm posted $5.24 earnings per share. On average, research analysts anticipate that United Therapeutics Co. will post 24.71 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on UTHR shares. Morgan Stanley cut shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $310.00 to $321.00 in a research report on Thursday, July 11th. HC Wainwright reaffirmed a “buy” rating and issued a $400.00 target price on shares of United Therapeutics in a report on Thursday, August 1st. Oppenheimer lifted their target price on shares of United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a report on Wednesday, August 28th. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Tuesday, August 20th. Finally, TD Cowen lifted their target price on shares of United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $357.17.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 7,794 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $355.54, for a total transaction of $2,771,078.76. Following the transaction, the chief financial officer now owns 5,344 shares in the company, valued at $1,900,005.76. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, COO Michael Benkowitz sold 25,000 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $323.38, for a total value of $8,084,500.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $833,350.26. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO James Edgemond sold 7,794 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $355.54, for a total transaction of $2,771,078.76. Following the completion of the transaction, the chief financial officer now owns 5,344 shares in the company, valued at approximately $1,900,005.76. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 105,238 shares of company stock worth $35,612,493 over the last three months. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.